In this episode, we dive into a massive multicenter study involving over 74,000 hospital admissions across 44 children’s hospitals to explore the evolving role of ketamine in treating Sickle Cell Disease (SCD). For those living with SCD, "vaso-occlusive crises" are a brutal reality—rigid, sickle-shaped blood cells block blood flow like a dam, leading to oxygen deprivation and excruciating pain. While opioids have long been the first-line defense, many patients find their pain remains uncontrolled, leading to a dangerous cycle of tolerance and "opioid-induced hyperalgesia," where the medication actually makes the body more sensitive to pain.

Ketamine offers a way to break this cycle by acting as an "opioid-sparing adjunct." As discussed in the transcript, ketamine targets the NMDA receptor, which functions like a "volume dial" for pain signa ...